Home › Funds › CAXTON CORP › IKT

CAXTON CORP position in IKT

INHIBIKASE THERAPEUTICS INC · Health Care

CAXTON CORP reported holding 28,453 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$58K, representing 3.12% of its reported portfolio and ranking #9 among its reported holdings. CAXTON CORP has disclosed IKT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)28.45K sh
Reported value held$57.76K
Portfolio Weight3.12%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How CAXTON CORP's IKT position evolved

CAXTON CORP first disclosed a stake in IKT in Q4 2024 at 16,393 shares (US$53K). The position peaked in Q4 2025 at 28,453 shares, worth US$58K. Across 7 filings, CAXTON CORP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 28,453 shares valued at US$58K. Notable position changes include a 74% increase in Q4 2025 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 16.39K $53.28K New
Q1 2025 16.39K $35.90K Hold
Q2 2025 16.39K $31.97K Hold
Q3 2025 16.39K $26.56K Hold
Q4 2025 28.45K $58.33K Add
Q1 2026 28.45K $47.80K Hold
Q2 2026 28.45K $57.76K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IKT and 13F data

IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.4M), Soleus Capital Management, L.P. (US$22.1M), Trails Edge Capital Partners, LP (US$18.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IKT

All IKT fund holders →

FAQ

How long has CAXTON CORP held IKT?

CAXTON CORP has disclosed IKT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is CAXTON CORP's current position in IKT?

As of Q2 2026, CAXTON CORP holds 28.45K shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $57.76K, representing 3.12% of its reported portfolio and ranking #9.

Has CAXTON CORP been buying or selling IKT?

In the latest 13F filing (Q2 2026), CAXTON CORP held unchanged its position in IKT. The position peaked in Q4 2025 at 28.45K shares.

Which other funds hold IKT?

Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.